NCT04653727 (AtemNHK) is a clinical trial of Cross-sectional survey in Covid19, sponsored by Charite University, Berlin, Germany.

Who is sponsoring NCT04653727?

NCT04653727 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT04653727?

Interventions in NCT04653727: Cross-sectional survey.

What condition does NCT04653727 study?

NCT04653727 studies Covid19, Influenza A, Respiratory Disease.

Is NCT04653727 still recruiting?

NCT04653727 is currently completed. Last updated 29 September 2022.

Last reviewed 2022-09-29 · How we verify

NCT04653727: AtemNHK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19

Completed Last updated 29 September 2022

What this trial tests

trial testing Cross-sectional survey in Covid19 in 1,287 participants. Completed in 5 March 2021.

Timeline

6 January 2021

Primary endpoint
5 March 2021

5 March 2021

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,287
Start date	6 January 2021
Primary completion	5 March 2021
Estimated completion	5 March 2021
Sites	1 location across Germany

Drugs / interventions tested

Cross-sectional survey

Conditions studied

Covid19 — all drugs for Covid19 →
Influenza A — all drugs for Influenza A →
Respiratory Disease — all drugs for Respiratory Disease →

Sponsor

Charite University, Berlin, Germany

Who can join

Adults 18 to 99, any sex, with Covid19 or Influenza A. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020. Since then, the virus has spread internationally and the WHO has classified the outbreak as a pandemic. In the context of the increasing reporting of this pandemic and the increasing governmental measures to limit or slow down the spread of SARS-CoV-2 by all means, there is so far little scientific evidence for the effects of a healthy lifestyle on the disease. The aim of this study is to compare the potential of different, possibly protective lifestyles using the example of the COVID-19 pandemic. We will conduct an online survey with 3.000 participants using mobile website technology.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments.
Wang X, Li J, Liu H, Hu X, et al · · 2023 · cited 7× · PMID 36985154 · DOI 10.3390/microorganisms11030580
Self-care and lifestyle interventions of complementary and integrative medicine during the COVID-19 pandemic-A cross-sectional study.
Jeitler M, Erehman A, Koppold DA, Ortiz M, et al · · 2022 · cited 5× · PMID 36698795 · DOI 10.3389/fmed.2022.1033181

Verify or expand the search:

Other trials of Cross-sectional survey

Trials testing the same drug.

NCT05530720 — Acceptance of Complementary Medicine in Germany · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04653727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 29 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04653727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing